07:20 AM EDT, 09/18/2026 (MT Newswires) -- Sanofi's (SAN.PA) rabies vaccine VaxRabeo was recommended for approval by the European Medicines Agency's Committee for Medicinal Products for Human Use, according to a Friday release. The vaccine, manufactured by the French drugmaker's Sanofi Winthrop Industrie, is intended for pre-exposure and post-exposure prophylaxis against rabies. The European Commission is expected to issue its final decision in the near future.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.